This may be due to the differences in residual activity of ET, which is 0% in the homozygous knockout mice, 15–20% in the fibroblasts of ET patients and 65–80% in the heterozygous mice due to upregulation of the expression of the Pcyt2 remaining allele. This evidence concerns the gene PCYT2 and essential thrombocythemia.